Ruchi Gupta
Head of Biomarkers Gilead Sciences
Seminars
Wednesday 22nd July 2026
Panel Discussion: Positioning Novel Mechanisms in the Myasthenia Gravis Market to Deliver Differentiated Patient Benefit
8:30 am
- Comparing how FcRn inhibition, complement blockade, B-cell depletion and CAR-T differ mechanistically and where each may sit best based on disease biology
- Examining how mechanistic sequencing could address patients exposed to prior lines of therapy without clear biomarkerguidance
- Identifying emerging strategies for treating MG patients who fail FcRn inhibition, IgG degraders or complement therapies
- Gain insight into how to position assets in a saturated market while addressing inadequate responders and future curative ambition
Wednesday 22nd July 2026
Interactive Audience Q&A: What’s Next for Biomarkers & Clinical Trial Design in Myasthenia Gravis & Autoimmune Neuropathies?
9:30 am
- Exploring the biggest unresolved challenges in biomarkers, patient stratification and clinical trial design across MG, CIDP, GBS and MMN, identifying where the field still lacks consensus and where future research should focus
- Separating established scientific understanding from emerging hypotheses by examining which biomarkers, endpoints and development strategies continue to add value, and which are becoming less informative as the treatment landscape evolves
- Opportunities to strengthen translational research, improve trial design and accelerate precision medicine across heterogeneous patient populations
